Literature DB >> 34316031

Repeated cocaine administration upregulates CB2 receptor expression in striatal medium-spiny neurons that express dopamine D1 receptors in mice.

Hai-Ying Zhang1,2, Lindsay De Biase3, Ramesh Chandra4, Hui Shen5, Qing-Rong Liu6, Eliot Gardner5, Mary Kay Lobo4, Zheng-Xiong Xi7.   

Abstract

Cannabinoid CB2 receptors (CB2R) are importantly involved in drug reward and addiction. However, the cellular mechanisms underlying CB2R action remain unclear. We have previously reported that cocaine self-administration upregulates CB2R expression in midbrain dopamine (DA) neurons. In the present study, we investigated whether cocaine or heroin also alters CB2R expression in striatal medium-spiny neurons that express dopamine D1 or D2 receptors (D1-MSNs, D2-MSNs) and microglia. Due to the concern of CB2R antibody specificity, we developed three mouse CB2-specific probes to detect CB2R mRNA using quantitative RT-PCR and RNAscope in situ hybridization (ISH) assays. We found that a single injection of cocaine failed to alter, while repeated cocaine injections or self-administration dose-dependently upregulated CB2R gene expression in both brain (cortex and striatum) and periphery (spleen). In contrast, repeated administration of heroin produced a dose-dependent reduction in striatal CB2 mRNA expression. RNAscope ISH assays detected CB2R mRNA in striatal D1- and D2-MSNs, not in microglia. We then used transgenic CX3CR1eGFP/+ microglia reporter mice and D1- or D2-Cre-RiboTag mice to purify striatal microglia or ribosome-associated mRNAs from CX3CR1eGFP/+, D1-MSNs, or D2-MSNs, respectively. We found that CB2R upregulation occurred mainly in D1-MSNs, not in D2-MSNs or microglia, in the nucleus accumbens rather than the dorsal striatum. These findings indicate that repeated cocaine exposure may upregulate CB2R expression in both brain and spleen, with regional and cell type-specific profiles. In the striatum, CB2R upregulation occurs mainly in D1-MSNs in the nucleus accumbens. Given the important role of D1-MSNs in brain reward function, the present findings provide new insight into mechanisms by which brain CB2Rs modulate cocaine action.
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  CB2 receptor; D1-MSNs; cannabinoid; cocaine; microglia; self-administration

Mesh:

Substances:

Year:  2021        PMID: 34316031      PMCID: PMC8975868          DOI: 10.1038/s41401-021-00712-6

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  71 in total

1.  Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal.

Authors:  Ai-Ling Li; Xiaoyan Lin; Amey S Dhopeshwarkar; Ana Carla Thomaz; Lawrence M Carey; Yingpeng Liu; Spyros P Nikas; Alexandros Makriyannis; Ken Mackie; Andrea G Hohmann
Journal:  Mol Pharmacol       Date:  2018-11-30       Impact factor: 4.436

2.  Increased vulnerability to cocaine in mice lacking dopamine D3 receptors.

Authors:  Rui Song; Hai-Ying Zhang; Xia Li; Guo-Hua Bi; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

Review 3.  The endocannabinoid system and the brain.

Authors:  Raphael Mechoulam; Linda A Parker
Journal:  Annu Rev Psychol       Date:  2012-07-12       Impact factor: 24.137

4.  Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction.

Authors:  Rebecca Hartzell Robinson; Joseph J Meissler; Jessica M Breslow-Deckman; John Gaughan; Martin W Adler; Toby K Eisenstein
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-04       Impact factor: 4.147

Review 5.  Progress in brain cannabinoid CB2 receptor research: From genes to behavior.

Authors:  Chloe J Jordan; Zheng-Xiong Xi
Journal:  Neurosci Biobehav Rev       Date:  2019-01-03       Impact factor: 8.989

Review 6.  Marijuana and cannabinoid regulation of brain reward circuits.

Authors:  Carl R Lupica; Arthur C Riegel; Alexander F Hoffman
Journal:  Br J Pharmacol       Date:  2004-08-16       Impact factor: 8.739

7.  Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release.

Authors:  Daniel J Foster; Jermaine M Wilson; Daniel H Remke; M Suhaib Mahmood; M Jashim Uddin; Jürgen Wess; Sachin Patel; Lawrence J Marnett; Colleen M Niswender; Carrie K Jones; Zixiu Xiang; Craig W Lindsley; Jerri M Rook; P Jeffrey Conn
Journal:  Neuron       Date:  2016-09-08       Impact factor: 17.173

Review 8.  The peripheral cannabinoid receptor knockout mice: an update.

Authors:  N E Buckley
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

9.  Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.

Authors:  Javier Palazuelos; Tania Aguado; M Ruth Pazos; Boris Julien; Carolina Carrasco; Eva Resel; Onintza Sagredo; Cristina Benito; Julián Romero; Iñigo Azcoitia; Javier Fernández-Ruiz; Manuel Guzmán; Ismael Galve-Roperh
Journal:  Brain       Date:  2009-10-05       Impact factor: 13.501

10.  The cannabinoid CB2 receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence.

Authors:  Vishakh Iyer; Richard A Slivicki; Ana C Thomaz; Jonathon D Crystal; Ken Mackie; Andrea G Hohmann
Journal:  Eur J Pharmacol       Date:  2020-09-05       Impact factor: 4.432

View more
  3 in total

Review 1.  Role of Cannabinoid CB2 Receptor in Alcohol Use Disorders: From Animal to Human Studies.

Authors:  María Salud García-Gutiérrez; Francisco Navarrete; Ani Gasparyan; Daniela Navarro; Álvaro Morcuende; Teresa Femenía; Jorge Manzanares
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

Review 2.  Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits.

Authors:  Anthony S Ferranti; Daniel J Foster
Journal:  Front Neurosci       Date:  2022-08-11       Impact factor: 5.152

Review 3.  Biomarkers of the Endocannabinoid System in Substance Use Disorders.

Authors:  Francisco Navarrete; María S García-Gutiérrez; Ani Gasparyan; Daniela Navarro; Francisco López-Picón; Álvaro Morcuende; Teresa Femenía; Jorge Manzanares
Journal:  Biomolecules       Date:  2022-03-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.